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Abstract Airwayhypersecretionismediatedbyincreasedreleaseof inflammatorymediators andcanbeimprovedby
inhibition of mediator production.We have recently reported that 1.8-cineol (eucalyptol) which is known as the major
monoterpene of eucalyptus oil suppressed arachidonic acidmetabolism and cytokine production in humanmonocytes.
Therefore, the aimofthis studywasto evaluatethe anti-inflammatoryefficacyof1.8-cineolbydeterminingitsprednisolone
equivalent potency in patients with severe asthma.Thirty-two patients with steroid-dependent bronchial asthma were
enrolled in a double-blind, placebo-controlled trial. Afterdetermining the effective oral steroid dosage duringa 2month
run-in phase, subjects were randomly allocated to receive either 200mg1.8-cineol t.i.d. or placebo in small gut soluble
capsules for12 weeks.Oral glucocorticosteroids were reduced by 2.5mg increments every 3 weeks.The primary end
point of this investigation was to establish the oral glucocorticosteroid-sparing capacity of 1.8-cineol in severe asthma.
Reductions in daily prednisolone dosage of 36% with active treatment (range 2.5^10mg, mean: 3.75mg) vs. a decrease
of only 7% (2.5^5mg, mean: 0.91mg) inthe placebo group (P=0.006) were tolerated.Twelve of16 cineolvs. fouroutof16
placebopatients achieved a reduction oforal steroids (P=0.012).Long-term systemic therapywith1.8-cineolhas a signifi-
cant steroid-savingeffect in steroid-dependingasthma.This is the firstevidence suggestingan anti-inflammatoryactivity
of the monoterpene 1.8-cineol in asthma and a new rational for its use as mucolytic agent in upper and lower airway
diseases. r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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In nature, essential oils are widely known as mixtures of
variousmonoterpenes that are used traditionally inman
in consequence of their secretolytic properties. Irrita-
tion of the airways and acute bronchospastic reactions
following inhalation or ingestion of these natural mix-
tures of monoterpenes has limited their clinical use. By
contrast, saturated monoterpenes, such as 1.8-cineol
(eucalyptol), the major constituent of eucalyptus oil is
well tolerated. This volatile oil has been used in tradi-
tional medicine as a secretolytic remedy for bronchitis,
sinusitis, and colds.Received 28 May 2002, accepted in revised form12 August 2002.
Correspondence should be addressed to: Priv.-Doz.Dr Uwe R.
Juergens, Abteilung Pneumologie,Medizinische UniversitCts-Poliklinik,
Wilhelmstrasse 35^37,D-53111Bonn,Germany.Fax: +49 / 228 287-
2266; E-mail: uwejuergens@t-online.deBiochemical, 1.8 -cineol, and other terpenes such as
menthol or camphor are isoprenoids (C5) consisting of
2-isoprene subunits (C10).They are related to human iso-
prenoids such as sesquiterpenes (C15), steroid hormones
(2C15), as well as glucocorticosteroid and tocopherols
(C20), each of which contains increasing numbers of iso-
prene subunits. Inhibition of the cyclooxygenase path-
way was reported as ¢rst evidence of a potential anti-
in£ammatory activityof1.8 cineol (1). Since in£ammatory
mediators areknown to inducehypersecretionby stimu-
lation of Cl secretion into the airways (2,3), wehave re-
cently reported that the monoterpene 1.8-cineol
revealed a steroid-like suppression of arachidonic acid
metabolism and cytokine production in vitro (4). Further-
more, 1.8-cineol showed a dose-dependent inhibition of
monocyte mediator production at therapeutic
plasma levels in vitro with a magnitude of inhibition
comparable to thatof budesonide (5).Further controlled
studies revealed a signi¢cant improvement in lung
ANTINFLAMMATORYACTIVITYOFEUCALYPTOL 251function tests (6,7) and in a non-controlled study
signi¢cant inhibition of LTB4 and IL-1b in stimulated
monocytes ex vivo after additional therapy with
200mg 1.8 -cineol t.i.d. administered in enteric-coated
capsules (8).
In Germany,1.8-cineol is registered as alicensedmedic-
inal product and available since many years in small gut-
soluble capsules (SoledumTM capsules,Cassella-med,Co-
logne,Germany) containing100mgcineol per capsule for
the treatment of acute and chronic bronchitis, sinusitis,
and respiratory infections. 1.8 -Cineol is well tolerated
at a dosage of 600mg/day (32 capsules), and should
be taken with cold water about 20min prior to eating
to prevent epigastric pain.Overweightmay be critical to
achieve steady-state plasma concentrations, which are
normally reached following 2^3 days of dosing because
of thehighly lipophilic nature of the substance.1.8 -Cineol
is extensively distributed into tissues and has a long
terminal half-life, which re£ects the slow release of the
monoterpene from these tissues back into plasma after
dosing has ceased. Following chronic administration
(800mg/day), no accumulation of cineol is known in the
plasma.
To establish whether the inhibitory e¡ects of 1.8 -ci-
neol on in£ammatory mediator production may also
translate into clinically relevant anti-in£ammatory e⁄-
cacy, we performed a randomised, placebo-controlled
trial to determine the oral glucocorticosteroid-saving ef-
¢cacyof long-termcineol therapy in patientswith severe
asthma.TABLE 1. Baseline demographics and concomitanttherapy*
Ci
Male :Female 1
Age (years) 59
Prednisolone dose (mg) 10.3
FVC [l] 4.6
FEV1 [l] 2.8
%FEV1pred 85
FEV1/FVC 61
PEFR [l/min] 388
RAW (kPa/(l/s)) 0.31
Concomitantdaily asthmamedication (n Pt.)
Inhaled steroids (mg) 830
(
Theophylline (mg) 796
(
Formoterol (mg) 1
(
Ipratropiumbromide (mg) 167
(
*Data are presented asmean7SD unless otherwise indicated.PATIENTSANDMETHODS
Study subjects
Thirty-two patients aged 32^75 years who met NHLBI
criteria for the diagnosis of bronchial asthma (9)were re-
cruited from our asthma outpatient clinic at Bonn Uni-
versity Hospital. Three asthmatics were aspirin-
sensitive and eight patients had chronic rhinosinusitis,
with or without nasal polyps, equally distributed in both
groups; six patientswere smokers (2o5 and 4o10 cigar-
ettes/day). Body weight in the placebo group (7472kg)
was not statistically di¡erent (P=0.36) from the verum
group (78714kg). Previous treatment with 1.8-cineol
was at leastwithdrawn 6weeksbeforepatient selection.
All asthmatics were receiving between 5 and 24mg pre-
dnisolone daily as the lowest maintenance dose. Both
groups were treated not statistically di¡erent with high
doses of inhaled corticosteroids from metered dose in-
halers expressed as equivalent doses to beclomethasone
dipropionate (BDP) in the verum and placebo groups
(Table 1). One pu¡ BDP (100mgpu¡1=valve dose)
was calculated as equivalent to 1 pu¡ £unisolide
(250 gpu¡1),1pu¡ budesonide (100mgpu¡1) and1
pu¡ £uticasonepropionate (50mgpu¡1). Additionally,
patients were on appropriate asthma treatment includ-
ing long-acting inhaled b-agonists and/or theophylline.
Dosages were kept constant throughout the study
except for short-acting b-agonists, which were used as
required with an average frequency of 3 2 pu¡s/day.
Daily prednisolone dosage and concomitant asthmaneol Placebo P-value
2:4 6:10 0.0277
710 56715 0.5349
74.4 11.975.7 0.2834
71.4 3.471.0 0.0869
71.4 2.270.9 0.117
730 78726 0.6501
716 63713 0.9750
7186 3537107 0.8139
70.16 0.3770.13 0.2115
7190
16)
11007200
(16)
0.1941
797
14)
716775
(15)
0.6496
9.6
10)
18.770.8
(11)
0.5463
715
13)
154714
(14)
0.1088
252 RESPIRATORYMEDICINEmedications didnotdi¡er in the two groups (Table1).For
patient inclusion, a reversibility of at least 15% in forced
expiratory volume in1s (FEV1) 10min after inhalation of
200mg fenoterol, and an airwayresistance (RAW)below
0.6kPa(l/s) was required. Lung function criteria and va-
lues conformed to ATS guidelines. Prior to patient inclu-
sion and at the end of the study, blood counts and
complete chemical analyses were performed.1.8 -Cineol
in small gut-soluble capsules taken 20min before eating
at a daily dosage of 3200mg had no taste or smell in
patients with a body weight460kg.
Exclusion criteria were BMIindex427, pregnancy and
lactation, known hypersensitivity to essential oils, treat-
ment with other secretolytic agents and leucotriene antago-
nists. No further changes in asthma medication were
allowed during the last 4 weeks prior to starting study
medication. Patients with respiratory infections within
6 weeks before study entry were excluded.
All patients gave written informed consent to take
part.The Human Ethics Committee of Bonn University
Hospital approved the study.The trial was conducted in
accordance with current good clinical practise (GCP)
guidelines.
Study design
This was a prospective, randomised, double-blind, and
placebo-controlled trial. Each participant was randomly
assigned either to 1.8-cineol (SoledumTM Capsules, Cas-
sella-med, Cologne,Germany) 200mg t.i.d. (at 8 a.m., 2
p.m., and 8 p.m.) or placebo capsules (Cassella-med) of
identical appearance.Cineol was taken in small gut-solu-
ble capsules with no taste or smell, if taken 20min prior
eating.Randomisation of patients and allocation conceal-
mentwasmade using the rancode system (IDV,Gauting,
Germany). The Study visits were performed on recruit-
ment and at 3, 6, 9, and 12 weeks as outpatients. All pa-
tients were assigned to a run-in phase of 2 months with
an additional visit (4 week) to ascertain that the asth-
ma was stable at the lowest e¡ective systemic steroid
dose. Stable asthmawas assured prior to randomisation
and at each following visit using measurements of lung
function, peak £ow and asthma scores on validated
scales. Compliance was monitored in both groups by
counting the remaining study medication at each visit of
the randomisation phase.
Each patient used a mini-Wright peak-£ow meter to
measure (best of three expiratory manoeuvres) daily
morning and evening PEFR (peak expiratory £ow rate).
Use of short-acting inhaled bronchodilators for relief of
acute dyspnoea was also documented. Asthma symp-
toms were derived from validated scales to assess the
intensity and frequency of dyspnoea and the severity
of cough. Using these validated scales, patients and
the study physician were asked to assess the e⁄cacy oftreatment at the end of study (or withdrawal from the
study).
Each study visit was planned to take place between 8
and10 a.m.Lung function tests includingbodyplethysmo-
graphy (Masterscreen, JCger,Germany) were performed
at each visit, and venous blood was taken to determine
blood-cell counts andbiochemical pro¢les at study entry
and at the ¢nal study visit.
GLUCOCORTICOSTEROID
REDUCTIONPROTOCOL
Prior to randomisation, all patients were stable on the
minimal e¡ective systemic steroid dose for at least 4
weeks. After randomisation, the study physician at the
outpatient clinic saw the patients at 3-week intervals
and in addition, if asthma symptoms had increased in be-
tween two visits. Provided their asthma was stable
(RAWo0.6 kPa/(l/s), averagemorning/evening peak £ow
o20%, increase in b2-adrenergics use by o30%), oral
steroids were reduced by 2.5mg at each visit (or 5mg, if
the long-term dosagewas20mg/day) for the following
3 weeks up to the next visit. Exacerbations compared to
baseline were decrease in the average morning/evening
peak £ow by 430%, decrease of mean daily peak £ow
by430%, or increased use of inhaled b-agonists as res-
cuemedication by430%, or increase in RAW by430%
at the time of the 3-week revaluation. In case of a wor-
sening trend in patients not reaching the exact criteria,
prednisolone 2.5mg was reduced, and the patient was
informed to see the study physician if symptoms in-
creased.
Statistical analysis
For eachpatient, the lowest oralglucocorticosteroid do-
sage which maintained stable clinical conditions for at
least 3 weeks was determined, as was the duration of
tolerated steroid reduction. Primary outcome measure
was the change from the baseline of oral steroid dosage.
Secondary e⁄cacy criteriawere duration of dose reduc-
tion tolerated and stable lung function as determined by
bodyplethysmography, stable clinical condition as mea-
suredbyoutpatient PEFR, symptom scores andbroncho-
dilators use, and overall assessment of e⁄cacy by the
patient and the study physician. Outcome measure size
was based on an estimated di¡erence of 3mg steroid re-
ductionbetween the two groups (a0.05, b0.10)result-
ing from a sample size estimation of16 patients for each
group (statistics N, IDV,Gauting,Germany).Theminimal
clinical relevant di¡erence was estimated a priori by
2.5mg prednisone that was equal to one steroid reduc-
tion step. For analysis of diary-card data of each patient,
means of daily PEFR, the average morning/evening PEFR
and symptom scores were calculated for each 3-week
FIG 1. Individual steroid doses before and after treatment. Pa-
tients who tolerated a reduction in oral steroid dosage are indi-
cated with dark symbols and patients who withdrew from the
study due to clinical deterioration as clear symbols. Twelve pa-
tients receiving 1.8-cineol and four placebo patients had their
steroid dosages reduced as shown by the connecting lines. Ster-
oid dosages are not depicted for all cineol patients, if they were
the same: one patienton 20mgwasreduced to17.5mg; two pa-
tients on15mg, one of each was reduced to 7.5 and 5mg; four
patients on10mg, two patients of eachwere reduced to 7.5 and
5mg; three patients on 7.5mg, one patientof eachwas reduced
to 5, 2.5 and 0mg; two patients on 5mgwere reduced to 0mg.
ANTINFLAMMATORYACTIVITYOFEUCALYPTOL 253interval.Di¡erences between the1.8-cineol and the pla-
cebo recipients were assessedwith theWilcoxon Signed
Rank test (StatView 5.01, SAS Institute Inc., NC, USA).
Survival analysis (Kaplan^Meier) was used to examine
the e¡ects of 1.8 -cineol and placebo over time.
Di¡erences were considered signi¢cant if P was less
than 0.05.
RESULTS
Baseline characteristics
Thirty-threepatientsmeeting the entry criteriawere in-
cluded in the study and randomised to receive study
medication. One patient withdrew consent due to a
supervening illness, so the per protocol analysis was
based on 32 patients.
Patient demography, lung function and glucocorticos-
teroid medication at baseline are summarised inTable 1.
Glucocorticosteroid dosages and concomitant asthma
medication were equally distributed between the
groups, and lung function tests revealed comparable re-
sults. Only the male:female ratio di¡ered in the two
groups, resulting in a non-signi¢cant lower FEV1 in the
placebo group. All concomitant therapy was unchanged
on exit from the study.
Glucocorticoid-saving e¡ects (Table 2)
Individuals on1.8-cineol had their oral glucocorticoster-
oid reduced by a mean of 3.75mg (95% CI: 2.15^5.35mg)
whilemaintaining a stable clinical condition,whereas the
tolerated reduction was signi¢cantly lower in the
placebo group (mean: 0.91mg, 95% CI: 0.03^1.85mg,
P=0.006). The individual dosages at start and end of
treatment are shown in Fig. 1. The cumulative dosage
reductions achieved in each group throughout the 12-
week study were 60mg per day for 1.8-cineol as com-
pared to 14.5mg for placebo treatments. Cumulative
reductions of prednisolone dosages (2.5mg/3 weeks) as
compared to randomisation (visit 1) were tolerated in
the verum group at visit 2 (32.5mg in 13 patients,
P=0.0022), at visit 3 (40mg in eight patients, P=0.0117),
at visit 4 (30mg in four patients, P=0.0679), and visit 5
(30mg in threepatients,P=0.1088). In the placebo group,
the tolerated reduction of prednisolone dosages as
compared to randomisation (visit 1) was much less at
visit 2 (10mg in four patients, P=0.0679) and visit 3 (5mg
in one patient).
Only four patients treatedwith1.8 -cineol did not tol-
erate any decrease in glucocorticosteroid dosage in con-
trast to12 patients given placebo.Compared to placebo,
cineol recipients maintained their lung function four
times longerdespitereceiving lowerdosages ofpredniso-
lone (Table 2).Clinical e¡ects of glucocorticosteroid
reduction
Reduction of prednisone 2.5mg every third week (e.g.
visits1^5) had no signi¢cant impact on lung function and
PEFR in the verum group, if all patients in each group at
the di¡erent visits were statistically compared to base-
line (Table 3a). In this group, prednisone reduction also
did not signi¢cantly increase regular daily use of salbuta-
mol. By contrast, in the placebo group, PEFRwas signi¢-
cantly lower in 15 out of 16 patients after the ¢rst
reduction (visit 2) of prednisolone 2.5 (Table 3b).
Reduction of prednisolone in the placebo group did not
provoke any adverse e¡ects on lung function measure-
ments compared to baseline. However, in this group,
the use of salbutamol as rescue medication almost
increased 2-fold as compared to baseline and this
was signi¢cant after reduction of only 2.5mg at visit 2
(Table 3b).
Scores for frequency of dyspnoea (0=never, 1=rare,
2=occasional, 3=often, 4=very often, 5=persistent) be-
fore glucocorticosteroid reduction (visit1) were not sig-
ni¢cantly (P=0.29) di¡erent in the placebo (1.571.2,
n=16) and the verum (0.870.7, n=16) groups. After
reduction of prednisolone 2.5mg (visit 2), the score of
TABLE 2. E⁄cacyparametersa
Cineol Placebo P-value
Tolerated dose reductionper patient (mg) 3.75 0.91 0.006
Cumulative tolerated dose reduction steps
in relationto totalpossible stepsb 27/ 55 5/ 55 0.0001
Days stable onreduced dose 36.6 8.3 0.006
Patient’sglobal assessmentof e⁄cacyc 2.271.2 3.370.8 0.01
Studyphysician’sglobal assessmentof e⁄cacy 2.271.2 3.770.7 0.007
aData are presented asmeanormean7SD.
bOne step was equivalent to 2.5mg except in one patient with initial steroid dosages of420mg in whom the initial step was
5mg. In one patient, initial prednisolone of14mg/day was reduced by 2mg.The total number of possible dose reduction steps
was determined considering the patient’s initial dose and the duration of the study.For example, if the initial dosagewas 7.5mg,
three reduction steps (to 5, 2.5, and 0mg) were possible throughoutthe study.
cOn a 4-point scale (1: verygood, 2: good, 3: moderate,4: deterioration).
TABLE 3. Comparison of lung functiontests andrescue salbutamolbefore and after prednisone reduction*
Reduction of
prednisolone
(mg/3 weeks)
n FEV1 (L) P-value RAW kPa/(l/s) P-value PEFR
(l/min)
P-value Rescue salbutamol
(pu¡s/day)
P-value
(a) Verumgroup
0 16 2.8171.4 F 0.31670.158 F 3887186 F 2.673,1 F
2.5 16 2.9571.2 0.7532 0.28970.122 0.4955 3187130 0.5303 3.273.2 0.2249
5 12 2.7571.4 0.6465 0.3270.13 0.3465 4187206 0.0630 3.473.8 0.5839
7.5 6 2.7571.5 0.138 0.28270.19 0.2489 362785 0.0796 1.873.5 0.1797
10 4 2.6572.0 0.2733 0.29770.223 0.4652 353795 0.1441 2.073.5 1.0
(b) Placebo group
0 16 2.1870.89 F 0.37170.124 F 3537107 F 3.773.2 F
2.5 15 2.1670.69 0.9547 0.38170.144 0.7548 269790 0.0329 6.373.8 0.0093
5 4 2.2270.43 0.4652 0.3770.133 0.0679 2957149 0.6547 672 0.1797
7.5 0 F F F F
*Changes compared to baseline in lung function measurements and use of salbutamol (mean7SD) for all patients in each
group after reduction of prednisone 2.5mgevery thirdweek.
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bo group (2.871.3, n=15) compared to the verum group
(1.371.3, n=16).
Safety
1.8-Cineol was generally well tolerated. There were 12
adverse events in nine patients throughout the study:
Three patients on1.8-cineol and two on placebo experi-
enced upper respiratory tract infections, two patients
had back pain, severe headache, gastritis and heartburn
in the1.8 -cineol group or abdominal discomfort and ton-
sillitis during placebo treatment. Side e¡ects considered
by the study physician to be possibly attributable to ci-
neolwereheartburn andgastritis.Therewereno serious
adverse events (SAEs) or any clinically relevant abnorm-
alities in routine blood test parameters.Discussion
In the present double-blind trial, themajority of patients
with chronic asthma receiving oral 1.8 -cineol 200mg
t.i.d. remained clinically stable despite a mean reduction
of oral steroid dosage of 36% equivalent to 3.8mg/day.
This was in sharp contrast to the placebo group (7%
equivalent to 0.9mg/day), in which12 of16 patients were
not able to tolerate anydecrease of oral steroids accord-
ing topre-de¢ned stability criteria.Themeanduration of
the tolerated dose reduction during 1.8-cineol was four
times that in the placebo groupwith a four times greater
reduction of cumulative steroid doses in the verum
group. Therefore, this is the ¢rst report to suggest a
clinically relevant anti-in£ammatory activity of1.8 -cineol
in bronchial asthma.
Only four out of 16 patients receiving placebo toler-
ated a reduction of their steroid dosages by 2.5^5mg.
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lowest e¡ective steroid dose and represented a group of
steroid-dependent asthmatics. The placebos were indis-
tinguishable from the active drug unless the capsules
were a bit apart.Concomitantmedicationwas also com-
parable at baseline and was kept unchanged as long as
patients remained in the study.
Before randomisation, the two groups studied were
comparable in the severity of their asthma as deter-
minedby long-term systemic use ofprednisolone, conco-
mitant asthma medication including on demand use of
short-term b2-agonists, lung function tests, daily mea-
surements of peak expiratory £ow, scores for frequency
of dyspnoea and body weight. The groups studied dif-
fered only in that the male:female ratio was reversed,
but by the entirely comparable asthma parameters in
both groups, gender seems to be very unlikely to have
a¡ected the severity of asthma in this study. Adverse
events occurred infrequently. Heartburn and gastritis
were the sole side e¡ects,which the studyphysician con-
sidered to be attributable to cineol. There were no se-
vere adverse events at any time during the study.
Until recently, however, the scienti¢c literature has
contained very little clinical or experimental data on
1.8-cineol or related terpenes as anti-asthma medica-
tions. Relatively high concentrations of systemic 1.8 -ci-
neol were recently reported to display an inhibitory
e¡ect on the classic types of experimental in£ammation
in rats, i.e. paw oedema by carrageenan and cotton pel-
let-induced granuloma (10). Though 1.8-cineol has no
acute bronchodilators activity, a controlled study re-
ported on surprisingly strong bronchodilators e¡ects in
patients with asthma following oral therapy with 1.8-ci-
neol for 7 days (6). In a single-blind study, in patientswith
mild and moderate asthma, additional therapy with 1.8-
cineol over 3 days also improved lung function and sup-
pressed ex vivo-stimulated in£ammatory mediator pro-
duction in short-term cultures of peripheral monocytes
(8).These studiesgave ¢rstevidence that1.8-cineol could
interferewith in£ammatorymediator production as the
underlying mechanism of its mucolytic activity. As indi-
cated by the present study, long-term therapy with 1.8-
cineol is well tolerated and mediates an anti-in£amma-
tory activity equivalent to about 3mg prednisolone. In
this view, there is new evidence to support long-term
systemic therapy with1.8-cineol thatmightbe therapeu-
tically useful for treatment of asthma and COPD. Since
systemic glucocorticosteroids were reduced in our pre-
sent study, the bronchodilators activity of1.8 -cineol was
only seen in oneproportion of thepatients studied in the
verum group at visit 2 despite reduction of prednisolone
to 2.5mg.
The chemical relationship between the monoterpene
1.8-cineol andglucocorticosteroids, alsomembers of the
terpene family, raise the possibility that there is a com-
mon mechanism of in£ammatory mediator suppressionfor their anti-in£ammatory e⁄cacy. Further ¢ndings
from our own laboratory revealed that not only 1.8-ci-
neol, but also pure L-menthol, which is themajor consti-
tuent of mint oil was able to suppress in£ammatory
mediator production in stimulated monocytes in vitro
(11). By contrast, mint oil and its derivatives containing
menthol, were shown to induceprostaglandin and leuko-
trienes production in vitro, indicating potential pro-in-
£ammatory activities of natural mixtures of
monoterpenes (11). L-menthol was also shown in a dou-
ble-blind, placebo-controlled trial in patients with mild
asthma to reduce airway hyperresponsiveness and im-
prove asthma (12).
The leukotrienes (LT) LTC4 and LTD4, their precursors
(5-HETE), prostanoids (PGD2, PGF2), and certain cyto-
kine stimulate mucus production by human airway
epithelial cells (2,13,14). Therefore, our previous reports
suggested that the knownmucolytic e¡ects of1.8 -cineol
might be mediated through inhibition of in£ammatory
mediator production (4,8). By contrast, mixtures of var-
ious monoterpenes known as essential oils may induce
hypersecretion by increased cell activity and stimulation
of in£ammatory mediator production, rather than by
single secretolysis. This is supposed to be a major cause
for known side e¡ects of essential oils in asthma.
In conclusion, the present study supports for the ¢rst
time a clinically relevant anti-in£ammatory activity of
the terpenoid oxide 1.8-cineol and o¡ers new perspec-
tives for its long-term therapeutic use in airway diseases,
such as asthma. Its potential role for early systemic anti-
in£ammatory treatment of intermittent andmild persis-
tent asthma requiring high doses of inhaled glucocorti-
costeroid still needs to be de¢ned. Additional studies
with1.8-cineol in various in£ammatory and steroid-sen-
sitive disorders, such as allergic rhinitis and in£ammatory
bowel disease, seem necessary to better de¢ne its ther-
apeutic e⁄cacy in chronic in£ammatory diseases.
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